Treatment

test

ASTRO Releases Pamphlets on Lymphoma

The American Society for Therapeutic Radiology and Oncology (ASTRO) has published two new patient information brochures to help patients with lymphoma understand their treatment options. Radiation Therapy for Non- Hodgkins Lymphoma and Radiation Therapy for Hodgkins Lymphoma to help patients and their families understand how radiation therapy works to cure cancers of the lymphatic system.

Galiximab plus Rituxan Effective Against Follicular Lymphoma

Biogen Idec announced that a Phase II clinical study demonstrated that galiximab may be used in combination with Rituxan(R) (rituximab), and the combination may prolong event-free survival (EFS) in patients with relapsed or refractory, follicular non-Hodgkin's lymphoma (NHL)when compared to previous results with Rituxan monotherapy. Side effects of the combination are similar to treatment with Rituxan alone.

Velcade with & without Rituxan Shows Positive Activity Against Lymphomas

Millennium Pharmaceuticals today announced Velcade study results for the treatment of patients with indolent and mantle cell non-Hodgkin's lymphomas (NHL), and Waldenstom's Macroglobulemia at the 9th International Conference of Malignant Lymphoma in Lugano, Switzerland.

Leukine (Sargramostim) May Improve Efficacy of Rituxan in Non-Hodgkin's

The colony stimulating factor Leukine (sargramostim) may improve the efficacy of Rituxan (rituximab) in treating the most common form of Non-Hodgkin's lymphoma (NHL), according to research from researchers at The University of Texas M. D. Anderson Cancer Center presented at the 9th International Conference on Malignant Lymphoma.

Genasense plus Rituxan Reported Active in Patients with Relapsed Non-Hodgkin's Lymphoma

Genta Inc. today announced the presentation of clinical data reporting the safety and activity of Genasense(R), the Company's lead anticancer drug, in combination with rituximab (Rituxan(R); Genentech IDEC). The trial was conducted in patients with relapsed and refractory non-Hodgkin's lymphoma (NHL) by investigators from the M.D. Anderson Cancer Center, Houston, TX, McMaster University, Hamilton, Ontario, and the Fox Chase Cancer Center, Philadelphia, PA. The data were presented by the trial's principal investigator, Dr.

Parents Agree to Radiation After Girls Relapse

A standoff between the parents of a 12-year-old and Texas social workers and doctors over radiation treatment ended on Friday on a somber note with a medical report that the girl's Hodgkin's disease, which had seemed in remission, had reappeared.

State of Texas Seizes Hodgkin's Girl from Her Parents

Child welfare officials have seized a 12-year-old Hodgkin's lymphoma patient from her parents because they were keeping her from radiation treatment that doctors say she needs. Last weekend, the state assumed custody of Katie, who has already undergone chemotherapy (the doctors want her to have radiation in addition to the chemo, the parents are questioning the need).

Redesign of NCI Clinical Trials System

The US National Cancer Advisory Board (NCAB) today formally accepted 22 strategic recommendations designed to reshape and enhance the National Cancer Institute's (NCI) clinical trials system.

New Chemo Effective For Unresponsive non-Hodgkin's Lymphoma

A new combination of five chemotherapy drugs was tested as safe and effective for patients with poor prognostic refractory (unresponsive) or multiple disease recurrent aggressive non-Hodgkin's lymphoma (NHL), according to the results of a phase II trial.

Rituxan Maintenance Prolongs Response Length in Low Grade NHL

German researchers have reported that Rituxan(R) (rituximab) maintenance prolongs response duration in patients with relapsed follicular and mantle cell lymphomas receiving induction chemotherapy with or without Rituxan. The details of this randomized trial were reported at the 2005 annual meeting of the American Society of Clinical Oncology, May 13-17 in Orlando, Florida.